Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis-Reference-Cited by-同舟云学术

Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis

Published:2019-10-01 Issue:9 Volume:37 Page:478-488
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Zhu Xiaolei¹,Wu Shenhong²³

Affiliation:

1. Division of Primary Care, Department of Medicine, School of Medicine, State University of New York at Stony Brook, Stony Brook, NY, USA;

2. Division of Hematology and Oncology, Department of Medicine, School of Medicine, State University of New York at Stony Brook, Stony Brook, NY, USA;

3. Division of Hematology and Oncology, Department of Medicine, Northport VA Medical Center, Northport, NY

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07357907.2019.1670203

Reference35 articles.

1. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion

2. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines

3. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

4. Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

5. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rising mortality related to cardiovascular disease and prostate cancer amongst older men across the United States;Current Problems in Cardiology;2024-11

2. Cardiovascular risks of Asian patients on androgen-receptor-targeted agents for prostate cancer: a systematic review and meta-analysis;Prostate International;2024-08

3. Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis;Prostate Cancer and Prostatic Diseases;2024-01-24

4. Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood;Medicina;2023-12-30

5. Renal Function Parameters in Distinctive Molecular Subtypes of Prostate Cancer;Cancers;2023-10-16